Market Intelligence, Clinical Progress, and High-Purity Reagents for Alzheimer's Disease and Tauopathy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for phospho-Tau drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Phospho-Antigen | MAPT p (pT181/pT217/pS396) Recombinant Protein Site-specific phosphorylation, High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View MAPT p Products |
| Total Tau Control | MAPT Wild-Type / Mutant Proteins (P301L, S305N) Familial tauopathy mutations, Aggregation-competent forms. |
View MAPT Products |
| Gene Delivery | MAPT Promise-ORF / Lentivirus Full-length ORF with phosphomimetic variants for stable cell lines. |
View MAPT p Products |
| Benchmark Ab | Anti-Phospho-Tau (pT217/pT181) Reference Antibody Recombinant positive control for biomarker assays. |
View MAPT p Products |
| Validator | MAPT siRNA Set For knockdown verification and specificity controls. |
View MAPT Products |
| Upstream Pathway | GSK3β Recombinant Protein Primary Tau kinase, Enzymatic activity for in vitro phosphorylation. |
View GSK3B Products |
| Co-pathology Target | APP / Aβ Peptides Amyloid cascade interaction, Dual-pathology models. |
View APP Products |
| Microglial Regulator | TREM2 Recombinant Protein Neuroinflammation axis, Combinatorial therapy target. |
View TREM2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phospho-Site Specificity (pT217 vs pT181 discrimination) | Site-specific phosphorylated proteins with >95% purity, Verified by mass spectrometry |
| Aggregation State Standardization (Monomer vs Oligomer vs PHF) | Controlled fibrillization protocols, Oligomer-enriched preparations available |
| Blood-Brain Barrier Penetration Modeling | Human/Cyno/Mouse ortholog proteins with conserved phosphorylation sites |
| Cross-reactivity with MAP Family (MAP2, MAP4) | Strict sequence homology verification, Unique epitope mapping data provided |
| Diagnostic Assay Calibration (Simoa/MSD platforms) | Clinical-grade reference materials, Theoretical MW confirmed |
Live Phospho-Tau R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for phospho-Tau targeted therapeutics is intensifying. Major players are shifting focus from passive immunotherapy (e.g., anti-Tau mAbs) to a broader portfolio including active vaccines, small molecule aggregation inhibitors, bispecific BBB-penetrant antibodies, and advanced genetic medicines (ASOs/siRNA). As first-generation anti-Tau antibodies face blood-brain barrier penetration challenges, the next wave of R&D is targeting N-terminal phospho-epitopes (pT217/pT181) for enhanced neuronal uptake and microglial engagement. Concurrently, blood-based p-Tau biomarkers are revolutionizing patient stratification, creating dual-use demand for research reagents in both therapeutic development and diagnostic assay manufacturing. Key mutations such as P301L (FTD-associated) and S305N (Pick's disease) are essential for developing selective antibodies that distinguish pathological conformations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-Phospho-Tau mAb | Eli Lilly, Biogen, Roche | Alzheimer's Disease, Progressive Supranuclear Palsy | Epitope-specific binding validation (Need phospho-site specific antigens) |
| Active Vaccine | AC Immune, Janssen | Preclinical AD, Primary Tauopathy | Immunogenicity assessment (Need aggregation-state specific proteins) |
| Bispecifics (BBB-shuttles) | Denali Therapeutics, Roche | Neurodegeneration | Receptor Transport Assays (Need pure MAPT p standard for downstream detection) |
| ASOs / Gene Therapy | Ionis Pharmaceuticals | Frontotemporal Dementia | Intracellular Reduction Validation (Need Lentivirus cell lines & siRNA) |
| Small Molecule Inhibitor | TauRx, UCB | Mild Cognitive Impairment | Aggregation kinetics assay (Need monomer vs fibril controls) |
| Diagnostic Blood Test | C2N Diagnostics, Quanterix | Early Screening, Treatment Monitoring | Calibrator standardization (Need high-lot-consistency phospho-proteins) |